Lawrence P. Wennogle is President & Drug Discovery at Intra-Cellular Therapies, Inc. (ITCI). They have made 2 open-market trades across 1 company since 2014, most recently 2015-06-08.
CIK 0001585663
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ITCI | 126,500 | $16.7M |
| PrivateUnlisted | 112,500 | — |
| Total | $16.7M |
Shares reported on the most recent Form 4, priced at the 2015-06-09 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITCI | SELL · 10b5-1 | 2015-06-08 | 2015-06-09 | $26.84 | $671K | -24.0% | +1.4% | +1.4% |
| ITCI | SELL · 10b5-1 | 2014-10-16 | 2014-10-17 | $15.00 | $77K | -24.0% | +1.4% | +1.4% |
| ITCI | SELL · 10b5-1 | 2014-10-13 | 2014-10-15 | $15.00 | $54K | -24.0% | +1.4% | +1.4% |
| ITCI | SELL · 10b5-1 | 2014-10-08 | 2014-10-10 | $15.00 | $71K | -24.0% | +1.4% | +1.4% |
| ITCI | SELL · 10b5-1 | 2014-10-03 | 2014-10-07 | $15.00 | $247K | -24.0% | +1.4% | +1.4% |
| ITCI | SELL · 10b5-1 | 2014-09-15 | 2014-09-17 | $15.00 | $75K | -24.0% | +1.4% | +1.4% |
| ITCI | SELL | 2014-05-27 | 2014-05-29 | $15.00 | $75K | -24.0% | +1.4% | +1.4% |
| ITCI | SELL | 2014-05-22 | 2014-05-23 | $15.00 | $90K | -24.0% | +1.4% | +1.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.